Asian Fund for Cancer Research shared a post on LinkedIn:
“Glioblastoma (GBM) is a highly aggressive form of brain cancer that can hit patients and families hard.
AFCR is committed to promoting patient-centred solutions to find more effective treatments. We are also actively involved in leading projects such as:
- GBM AGILE – The world’s first GBM adaptive clinical trial platform
- PIONEER Oncology – Accelerating Brain Cancer Drug Innovation in Asia
Please join us in bringing breakthrough hope to patients.”
You can also read:
Glioblastoma Awareness Day 2025: Uniting for Progress and Hope
